Intriguingly,when the biodistribution of Ff-CD nanoparticles was corrected by usingthe data from nontargeted nanoparticles (βCD6), in contrastto the tumor and the liver, active targeting of Ff-CD was more successfulin the lungs although the nanoparticles were specifically engulfedby the FRβ+CD206+ macrophages. The gene discussed is FOLR2; the disease is neoplasm.